<DOC>
	<DOCNO>NCT02975440</DOCNO>
	<brief_summary>This study conduct single center , open-label study single group fix sequence design evaluate effect repeat oral administration 600 mg RIF ( Rifampicin ) give daily 11 day single oral dose pharmacokinetics VPR ( Vilaprisan ) MDZ ( Midazolam ) reference ( probe ) substance .</brief_summary>
	<brief_title>Drug-drug Interaction Study Between Orally Administered Rifampicin Vilaprisan</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy female postmenopausal subject Age : 45 65 year ( inclusive ) Body mass index ( BMI ) : ≥20 ≤32 kg/m² Race : White Any find medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Relevant diseases within last 4 week prior first drug administration Existing chronic disease require medication Known suspect malignant tumor ( include history malignant tumor , status treatment ) , know suspected benign tumor liver pituitary ( include treatment ) Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Regular use medicine Repeated use drug 1 week first study drug administration might affect absorption ( e.g . laxative , loperamide , metoclopramide , antacid , H2receptor antagonists )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vilaprisan</keyword>
	<keyword>PK</keyword>
	<keyword>rifampicin</keyword>
	<keyword>midazolam ,</keyword>
	<keyword>CYP3A4 induction</keyword>
	<keyword>drug-drug interaction</keyword>
</DOC>